Revvity Reports Q3 Revenue of $729M,
Revvity announced strong third quarter results, with pro forma revenue up 7% and adjusted EPS of $1.38. The company raised full-year guidance and announced the sale of its China Immunodiagnostics unit.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed